11.00

0.50% -0.055

After Hours: 11.00

Promis Neurosciences Inc (PMN)

Overview News Price History Financials Discussions Forecast Stock Split

Promis Neurosciences Inc stock is traded at $11.00, with a volume of 28,078. It is down -0.50% in the last 24 hours and up +0.36% over the past month. ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Previous Close:

$11.05

Open:

$11.02

24h Volume:

28,078

Relative Volume:

0.56

Market Cap:

$98.64M

Revenue:

Net Income/Loss:

$-39.72M

P/E Ratio:

-0.5993

EPS:

-18.3554

Net Cash Flow:

$-28.18M

1W Performance:

-1.35%

1M Performance:

+0.36%

6M Performance:

+12.62%

1Y Performance:

-23.48%

1-Day Range:

$10.88

$11.49

1-Week Range:

$10.88

$11.50

52-Week Range:

$6.27

$39.75

Promis Neurosciences Inc Stock (PMN) Company Profile

Name

Promis Neurosciences Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

416-847-6898

Address

SUITE 200, 1920 YONGE STREET, TORONTO

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

PMN's Discussions on Twitter

Compare PMN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PMN Promis Neurosciences Inc	11.00	99.14M	0	-39.72M	-28.18M	-18.36
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Promis Neurosciences Inc Stock (PMN) Latest News

Apr 26, 2026

ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN

Apr 26, 2026

Apr 24, 2026

ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN

Apr 24, 2026

PMN Price Today: ProMIS Neurosciences Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 24, 2026

Apr 23, 2026

Director Kirwin’s entity buys 4,000 ProMIS (PMN) shares at $11.33 - Stock Titan

Apr 23, 2026

PMN ProMIS Neurosciences Inc. Common Shares (ON) posts wider than expected Q4 2025 loss but still notches small share price gain today.Equity Raise - UBND thành phố Hải Phòng

Apr 23, 2026

Apr 18, 2026

ProMIS (PMN) Stock: Is It Overpriced in Market (Drifts Lower) 2026-04-18Fast Rising Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Apr 13, 2026

CEO Neil Warma to outline Alzheimer’s trial timeline at Apr. 21 event - Stock Titan

Apr 13, 2026

Winners Losers: Is ProMIS Neurosciences Inc stock a hidden gem2026 Breakouts & Breakdowns & Weekly High Return Forecasts - baoquankhu1.vn

Apr 13, 2026

What events could move ProMIS (PMN) Stock next | Price at $12.95, Up 2.78%Top Analyst Picks - Newser

Apr 13, 2026

Apr 10, 2026

PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill

Apr 10, 2026

Apr 09, 2026

Major holders and board changes in ProMIS Neurosciences (PMN) 2026 proxy statement - Stock Titan

Apr 09, 2026

Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Neuramedy, Promis Neurosciences, Enterin Inc., Nippon Chemiphar - Mena FN

Apr 09, 2026

ProMIS Neurosciences | DEFA14A: Others - Moomoo

Apr 09, 2026

Apr 08, 2026

PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Can ProMIS Neurosciences Inc continue delivering strong returns2026 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn

Apr 08, 2026

Analysis Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn

Apr 08, 2026

How does currency impact ProMIS (PMN) Stock | Price at $10.88, Down 0.73%Community Watchlist - Newser

Apr 08, 2026

Apr 07, 2026

ProMIS Neurosciences Shares Plunge Amid Critical Clinical Trial Phase - AD HOC NEWS

Apr 07, 2026

Janus Henderson (PMN) discloses 14.4% holding in PROMIS Neurosciences - Stock Titan

Apr 07, 2026

Apr 06, 2026

Is ProMIS (PMN) Stock Overpriced Now | Price at $11.05, Down 11.67%Industry Analysis - Newser

Apr 06, 2026

Apr 04, 2026

PMN Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Promis Neurosciences (NASDAQ:PMN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Apr 04, 2026

Apr 03, 2026

PMN Faces Selling Pressure: Technical Levels to Watch - Newser

Apr 03, 2026

Mar 31, 2026

Weekly Earnings: Will ProMIS Neurosciences Inc stock go up in YEARShare Buyback & Low Drawdown Investment Strategies - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Aug Volume: How does ProMIS Neurosciences Inc perform in inflationary periods2026 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn

Mar 30, 2026

Mar 27, 2026

ProMIS Neurosciences Inc expected to post a loss of $1.91 a shareEarnings Preview - TradingView

Mar 27, 2026

[EFFECT] ProMIS Neurosciences Inc. SEC Filing - Stock Titan

Mar 27, 2026

ProMIS Neurosciences | EFFECT: Others - Moomoo

Mar 27, 2026

Mar 26, 2026

Aug Mood: How cyclical is ProMIS Neurosciences Incs revenue stream2026 Institutional Moves & Low Risk Profit Maximizing Plans - baoquankhu1.vn

Mar 26, 2026

ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart

Mar 26, 2026

Mar 25, 2026

ProMIS Neurosciences (PMN) files $50M at-the-market sales supplement - Stock Titan

Mar 25, 2026

ProMIS Neurosciences 10-K: $0 Revenue, ($22.61) EPS, Net Loss $39.72M - TradingView

Mar 25, 2026

Alzheimer’s antibody lead and ALS programs at ProMIS (NASDAQ: PMN) - Stock Titan

Mar 25, 2026

ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 25, 2026

ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 - TradingView

Mar 25, 2026

Heavy 2025 loss but big AD bet for ProMIS Neurosciences (PMN) with $175M funding - Stock Titan

Mar 25, 2026

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - ChartMill

Mar 25, 2026

Mar 23, 2026

Promis Neurosciences (PMN) to Release Earnings on Monday - Defense World

Mar 23, 2026

Mar 22, 2026

How does ProMIS Neurosciences Inc perform in inflationary periods2026 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn

Mar 22, 2026

If You Invested $1,000 in Promis Neuroscie (PMN) - Stock Titan

Mar 22, 2026

Mar 20, 2026

Activity Recap: How cyclical is ProMIS Neurosciences Incs revenue streamDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn

Mar 20, 2026

Mar 18, 2026

ProMIS Neurosciences (PMN) registers 13.83M shares after $75.5M private placement - Stock Titan

Mar 18, 2026

Wellington holds 9.99% of ProMIS Neurosciences (NASDAQ: PMN) via shares and warrants - Stock Titan

Mar 18, 2026

ProMIS Neurosciences to Present Data on ALS & Parkinsons - GlobeNewswire

Mar 18, 2026

ALS, Parkinson’s vaccine data to debut at leading AD/PD 2026 meeting - Stock Titan

Mar 18, 2026

Mar 17, 2026